Top Markets
Coin of the day
Satsuma Pharmaceuticals, Inc. Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc.

STSA
Rank in Stocks #29910
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies for the rapid relief of migraines. Its lead therapeutic candidate, STS101, is an integrated drug-device system comprising a proprietary dry-powder formulation of dihydroergotamine mesylate. Currently, STS101 is progressing through its pivotal SUMMIT Phase 3 efficacy trials and is designed for self-administration via a specialized, pre-filled, single-use nasal delivery device. Established in 2016, the company maintains its headquarters in South San Francisco, California.
Share Price
$1.10
Last synced: 2023-06-07
Market Cap
$19.12M
Change (1 day)
-0.90%
Change (1 year)
0.00%
Country
US
Trade Satsuma Pharmaceuticals, Inc. (STSA)

Category

EPS for Satsuma Pharmaceuticals, Inc. (STSA)
EPS as of 2026 TTM: 0
According to Satsuma Pharmaceuticals, Inc. latest financial reports and stock price the company's current EPS (TTM) is 0. At the end of 2026 the company had a EPS of 0 equal to its 2026 EPS that were of 0.
EPS history for Satsuma Pharmaceuticals, Inc. from 2026 to 2026
EPS at the end of each year
Year EPS Change
Not enough data for the provided dates.
EPS for similar companies or competitors